...而原研药厂商为了减少因首仿药上市所造成的经济损失,在实践过程中采取了许多应对法律措施,其中“授权仿制药(authorized generics)”就是原研药厂商应对首仿药申请商 (本文共计1页).
基于16个网页-相关网页
包括辉瑞和默克在内的美国公司试图在专利到期前几个月推出自己的“授权仿制药”，以减轻仿制药带来的竞争影响。
American firms, including Pfizer and Merck, are trying to launch their own "authorised generics" a few months before patents expire to try to blunt the impact of competition.
大制药公司指出，授权的仿制药能够压低仿制品的价格。
The big drug firms point out that authorised generics drive down the price of copies.
然而，在通常情况下，第一个仿制药并不能在市场上自由的销售，因为专利所有人都会采取销售品牌药物的“授权”仿制药的措施进行干扰。
Often, however, the first generic does not have a free run, because patent-owners have taken to selling "authorised" generic versions of branded pills.
应用推荐